Latest News & Updates
Infinity Pharmaceuticals has entered into two separate agreements with Roche and AbbVie to develop and commercialize duvelisib (IPI-145), an oral inhibitor of PI3K-delta and PI3K-gamma, for the treatment of patients with hematologic malignancies.
At the 2014 ASCO meeting, OncologyLive sat down with Jimmie C. Holland, MD, the Wayne E. Chapman Chair in Psychiatric Oncology at Memorial Sloan Kettering Cancer Center and the recipient of the 2014 Giants of Cancer Care™ Award for her pioneering contributions in the field of supportive care.
More than one-third of patients with breast or ovarian cancer or a family history of those diseases who also saw a genetic counselor did not pursue genetic testing for BRCA 1 or BRCA 2 mutations.
A Biologics License Application has been submitted to the FDA for the bispecific T-cell engager (BiTE) antibody blinatumomab as a treatment for adult patients with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)
A preclinical study has shown promising steps toward tackling drug resistance in hematologic malignancies using sequential dosing of drugs targeted against vulnerabilities that emerge as a result of tumor evolution
Latest Peer Exchange Discussions
Brian I. Rini, MD, discusses initial findings for PD-L1 inhibitors as treatments for patients with bladder cancer. View Now
In this segment, Noopur Raje, MD, and Sagar Lonial, MD, discuss emerging agents and key trials of investigational drugs in patients with multiple myeloma. Ann McNeill, RN, MSN, APN, explains why enrollment in clinical trials may be suggested to patients prior to treatment with pomalidomide, carfilzomib, or combination therapy. View Now
The panelists discuss clinical, safety, and reimbursement issues related to the use of abiraterone and enzalutamide in patients with mCRPC. View Now
Most Popular Right Now
Online CME Activities